Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
This Week In Space podcast: Episode 204 — A New NASA - 2Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- 3Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- 4SF Chinatown's historic Empress of China building being revived into cultural campus
- 5African nations push to recognize crimes of colonialism in Algeria
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Two more UN peacekeepers killed in southern Lebanon: UNIFIL
- America's Confided in Fridge in 2024
- In these U.S. groups, deaths now exceed births. What’s happening?
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Overlooked infertility care should be part of national health services, says WHO
- Extraordinary Snowboarding Objections All over the Planet
- 5 Worldwide Road Food varieties You Should Attempt
